ALB and neoplasm: TACE combined with RFA plus sorafenib provided clinical benefit in almost all analyzed subgroups, despite some participants having characteristics associated with poor prognosis such as poor liver function (Child-Pugh B and albumin-bilirubin grade 2), a higher AFP level (>400 ng/ml), older age (>50 years), tumor without encapsulation and larger tumor (maximum diameter >7 cm) (Figure 4).